Summary Although cellular drug resistance is considered to be an important cause of the poor prognosis of children with relapsed acute lymphoblastic leukaemia (ALL), the knowledge of drug resistance in these patients is very limited. Different aspects of drug resistance were studied in 17 children with relapsed ALL. The in vitro sensitivity profile was determined using the MTT assay. Cells from relapsed children were significantly more resistant to 6-thioguanine, prednisolone, cytosine arabinoside, daunorubicin (DNR) The use of combination chemotherapy in children with acute lymphoblastic leukaemia (ALL) presently results in a complete remission rate of more than 95%. With the best currently available treatment, about two thirds of these children will remain in continuous complete remission and can therefore be considered cured. Patients suffering from a relapse however have a cure rate which is much lower. One of the main causes of this poor prognosis is probably a resistance of the leukaemic cells to a number of drugs used for treatment (Rivera et al., 1989) .
The use of combination chemotherapy in children with acute lymphoblastic leukaemia (ALL) presently results in a complete remission rate of more than 95%. With the best currently available treatment, about two thirds of these children will remain in continuous complete remission and can therefore be considered cured. Patients suffering from a relapse however have a cure rate which is much lower. One of the main causes of this poor prognosis is probably a resistance of the leukaemic cells to a number of drugs used for treatment (Rivera et al., 1989) .
At present the knowledge of drug resistance in childhood ALL is very limited. It is unknown how often, when, and for which drugs resistance is occurring. Currently, much attention is given to the multidrug resistance (MDR) phenomenon: a resistance to vinca-alkaloids and anthracyclines, mediated by the drug efflux pump P-glycoprotein (P-gp) , that can at least be partially overcome by so-called resistance modifiers. The clinical significance of MDR in childhood ALL is still unknown. Recently, we and others adapted and improved assays to detect drug resistance of leukaemic cells obtained from patients (Weisenthal et al., 1986; Bird et al., 1986; Hongo et al., 1987; Pieters et al., 1988 Pieters et al., , 1989 Campling et al., 1988; Twentyman et al., 1989) showing good correlations between in vitro results and clinical response to chemotherapy (Tidefelt et al., 1989; Sargent & Taylor, 1989; Santini et al., 1989; Bosanquet et al., 1991; Pieters et al., 1990 Pieters et al., , 1991 . Because of the development of these short-term assays it has recently become possible to study drug resistance of patients with ALL. In the present study we assessed the resistance profiles of children with relapsed ALL and the clinical relevance of the MDR model in these patients.
Materials and methods
Drug sensitivity assay Leukaemic cells were obtained from bone marrow and peripheral blood samples taken for routine diagnostic procedures. Preparation of mononuclear cell suspensions and drug solutions have been described earlier . In most cases, cells were used after cryopreservation. Patients with B-cell ALL characterised by the expression of surface immunoglobulins, were excluded from the study. Part of the samples were used in an earlier study .
Drug sensitivity was determined with the 4-day MTT assay as described earlier . Six concentrations of each drug were tested in duplicate. The drugs and range of end concentrations and dilution factors were: 6-thioguanine (6-TG, 1.56-50 jg ml-', 2-fold dilutions); vincristine (VCR, 0.05-50jIgml', 4-fold); prednisolone (Pred, 0.08-250jig ml-', 5-fold); daunorubicin (DNR, 0.002-2.0jigmI 1, 4-fold); mafosfamide (Maf, 0.10-100 jig ml-', 4-fold); cytosine arabinoside (Ara-C, 0.0024-2.5 jig ml-', 4-fold); mustine HCI (Must, 0.16-500 ig ml-', 5-fold); L-asparaginase (LAsp, 0.003-10 IU ml' 5-fold 
MDR parameters
The effects of the resistance modifiers cyclosporine A (SandimmuneR; CsA; 2 ttg ml-'), verapamil (Vp; 5 jg ml-') and lidocaine (40 jg ml-') upon leukaemic cell kill by VCR, DNR, and 6-TG or 6-mercaptopurine were tested using the MTT assay. The purine analogues, not belonging to the drugs involved in MDR, were incorporated in this part of the study to detect a possible non-specific effect of resistance modifiers. Accumulation studies were carried out as described elsewhere (Broxterman et al., 1987 (Broxterman et al., , 1988 . Briefly, the cells were incubated during 60min at 37°C with '4C-daunorubicin or 3H-vincristine in medium with 10% FCS and 20 mM Hepes, pH 7.45, with or without resistance modifiers as indicated. Cells were washed twice with ice-cold phosphate buffer saline and cell-associated radioactivity was quantitated by liquid scintillation counting. Cell area measurements were performed with a digitising interactive video overlay system (PRODIT, Promis, Almere, The Netherlands) at a final magnification of approximately 3000 x. Cells were selected up to a sample size of 100 according to the 'zone method' (van Diest et al., 1989) . P-glycoprotein staining of cytospun leukaemic cells was done with the monoclonal antibodies C219 and JSB-l using the Histostain-SP kit as described previously . Cells from the cell line 8226/Dox4, obtained from Dr W.S. Dalton (Arizona Cancer Center), showing a low multidrug resistance associated with P-gp expression were simultaneously stained and used as a weakly positive control (Dalton et al., 1989 Figure 1 .
Since for some drugs the LC50 values of untreated patients show a non-parametric distribution (see e.g. the Pred data in Figure 1 ) the mean and standard deviations are less adequate parameters to describe these data. This problem can be circumvented by using percentiles. For example, a sample in the 90th percentile (P90) means that this sample is more resistant than 90% of all samples tested. The P50 is identical to the median. The PlO, P50 and P90 of untreated ALL samples are shown in Figure 2 . Using the P90 of untreated patients as cut-off point of resistance, the resistance profiles of individual relapsed patients are presented in Figure 2 . Some patients (R3b, R7, R9) are resistant to almost all drugs tested while others (RI, R2, R8, RIO, R12, R15, R16, R17) are resistant to only 1-3 drugs.
In In order to study whether classic MDR plays a role in clinical resistance in ALL patients we studied several aspects of the MDR model:
(a) Cross resistance to vinca-alkaloids and anthracyclines As shown above the group of relapsed patients was significantly more resistant to DNR but not to VCR than the group of untreated ALL patients. Looking at individual cases (Figure 2) , a resistance to both VCR and DNR was found in two patients (R3b and R7) while in two others (R9, R16) cells were resistant to DNR but not to VCR. In all four cases however this was associated with resistance to other drugs which are not involved in the MDR model.
(b) P-gp expression P-gp staining was performed on cells from 28 untreated and 14 relapsed ALL samples (RI -3b, R7, R9-17). Cells from the positive control cell line 8226/Dox4, stained simultaneously, were clearly P-gp positive. All 42 cases, including the four cases who showed an in vitro resistance to DNR and VCR, were P-gp negative.
(c) Resistance modifiers Results of testing resistance modifiers were evaluable in 12 untreated and eight relapsed samples. CsA alone decreased LCS to 88 ± 38% (mean ± s.d.), Vp to 96 ± 12% and lidocaine to 96 ± 13%. In two samples CsA increased LCS dramatically to 143% and 160% respectively. In the first of these cases, CsA was tested in concentrations ranging from 0.06 to 2 igml-'. It appeared that the increased LCS was dose-dependent reaching a maximum of 158% at 0.5 pg ml' CsA followed by a decline to 143% at 2jugml1'. Figure 3 shows the ALL cell kill by combinations of resistance modifiers and cytostatic drugs corrected for the effect of the resistance modifiers alone. Addition of modifiers did not lead to a significantly increased cell kill by VCR, DNR, and thiopurines. In none of the combinations the influence of resistance modifiers upon cell kill by cytostatic drugs was significantly different between relapsed and untreated patients.
In three relapsed and seven untreated patients we studied the accumulation of DNR and VCR with and without Vp ( Table IV) . Vp did not enhance DNR accumulation (mean 96.4%, range 83-108%) while VCR accumulation was increased to a mean of 125% (range 81-168%). We also found that 16pJM Vp increases the VCR accumulation of normal peripheral blood lymphocytes to 120-130% (data not shown). Cells from case R3b which were highly resistant to VCR (LC50=41.0jigml-') and DNR (LC50=0.9 11gml-') did not accumulate less VCR or DNR than cells from nine other cases. Also, in this case, DNR-and VCR accumulation and -cytotoxicity were not influenced by resistance modifiers.
Discussion
Although chemotherapeutic regimens have dramatically improved the overall prognosis in childhood ALL the prognosis for those with relapsed ALL is still poor. Cellular drug resistance is most probably one of the main factors responsible for this fact. However, the knowledge about mechanisms and types of cellular drug resistance in childhood ALL is very limited.
Weisenthal et al. (1986) found that relapsed ALL patients were significantly more resistant to VCR, dexamethasone and doxorubicin but not to Must. For Ara-C the results depended on the concentration tested. In the present study we showed that a group of 11 children with relapsed ALL was significantly more resistant to DNR, 6-TG, Ara-C, alkylating drugs and Pred, but not to VCR and L-Asp than a group of 41 children with ALL at initial diagnosis. This suggests that L-Asp and VCR are not involved very often in drug resistance in children with relapsed ALL.
In both Weisenthal's study and the present study there were large overlaps in the ranges of LCso values of untreated and relapsed patients. When we evaluated the drug resistance profiles of individual children with relapsed ALL, large interindividual differences in the patterns of drug resistance and the degree of resistance were found. In some patients a general drug resistance was found while others were in vitro resistant to only one to three out of eight tested drugs. This might illustrate the fact that resistance of leukaemic cells to anticancer drugs is only one of the factors contributing to the poor prognosis in relapsed leukaemia. Interpatient pharmacokinetic variabilities are clearly related to the probability of oncolytic effects (Evans et al., 1989) . On the other hand, the large interindividual differences in drug resistance profiles suggest that for some patients combinations of effective antileukaemic drugs might be composed while this is not possible for those with a general resistance. Prevention of unnecessary toxicity caused by drugs to which the leukaemic cells are resistant is another goal to achieve. Larger studies might be very useful in designing new treatment protocols for the poor risk groups and perhaps even in tailoring chemotherapy for individual poor risk patients. The first data of a very recently published non-randomised study of Hongo et al. (1990) have to be handled with care but are encouraging: Eleven courses of chemotherapy based on the data of the MTT assay in children with relapsed leukaemia resulted in a response in nine cases compared to only six responses in 15
courses not based on the MTT assay. The numbers RI to R17 refer to the relapsed samples RI to R17 described in the text and tables. In this figure R3 refers to R3b. PIO, P50 and P90 represent the 10th, 50th ( = median) and 90th percentiles of LC50 values of the group of initial ALL patients, given in jig ml1' (except for L-Asparaginase which is in U ml-'). (Tawa et al., 1990; Rothenberg et al., 1989; Ubezio et al., 1989) . In other types of leukaemia it probably plays a more important role in clinical drug resistance (Mattern et al., 1989; Ma et al., 1987; Carulli et al., 1988; Sugawara et al., 1989 (Klumper et al., 1991) . Our samples were cryopreserved and the endpoint was the LC50 instead of cell kill at a single drug concentration. Also, the concentrations of modifiers were different and in the previous study the leukaemic cells were pre-incubated with modifiers for one hour. Finally, it might be that children from the previous study have been more heavily pretreated with VCR.
In two studies of adult ANLL in which MDR probably plays an important role, the effect of verapamil on uptake and cytotoxicity of anthracyclines was higher in cells from patients resistant to clinical chemotherapy (Maruyama et al., 1989; Tidefelt et al., 1988 tion of vinca-alkaloids and anthracyclines are not the only factors accounting for resistance to these classes of drugs (Ubezio et al., 1989; Rivera-Fillat et al., 1988) . Diversion to some cellular compartment might play a role. Changes in topoisomerases or disturbed intracellular drug distributions are other possible explanations. A remarkable phenomen was that CsA enhanced leukaemic cell survival in two cases. This has been observed earlier in tumour cell lines (Schuurhuis et al., 1990 ) and might be a warning against the use of CsA in clinical trials on reversal of drug resistance.
We conclude that children with relapsed ALL show varying types of drug resistance. Notwithstanding the fact that large interindividual differences exist in degree of resistance and number of drugs to which a resistance is detected, significant differences between relapsed and untreated patients were found in sensitivity to DNR, 6-TG, Pred, Ara-C and alkylating drugs but not in sensitivity to VCR and L-Asp. DNR-and VCR resistance in childhood relapsed ALL is not due to P-gp mediated MDR which is not an important mechanism of drug resistance in these patients. Future studies on clinical drug resistance in ALL should not only focus on P-gp expression but should incorporate data of in vitro drug sensitivity testing because this measures the end result of all mechanisms of drug resistance. The acquired knowledge of resistance could lead to improved therapies for children with relapsed ALL.
